NCT00323895已完成4 期
A Prospective, Randomized, Multi-Center Comparison of the CYPHER Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients With Intra-Des Restenosis
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 320
- 试验地点
- 3
- 主要终点
- In stent late loss.
研究概览
简要总结
A Prospective, Randomized, Multi-Center Comparison of the Cypher Select™ Sirolimus-Eluting Stent and Balloon Re-Angioplasty for Treatment of Patients with Intra-Des Restenosis.
详细描述
This is a prospective, randomized study to be conducted at up to 33 sites in France with 3 groups of patients (1 group with intra-Taxus™ restenosis, 1 group with intra-Cypher™ restenosis and 1 control group with intra-BMS restenosis). All patients will have a repeat angiography at 9 to 12 months post-procedure and will be followed up to 12 months post-procedure.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II-III) OR patients with documented silent ischemia;
- •Patient has an intra-DES (TAXUS™ OR CYPHER™) or intra-BMS restenosis of >= 50% and <100% (by QCA online of the MLD compared to the distal reference diameter) in a native coronary artery;
- •Study target lesion must be located in a restenotic native coronary artery >=2.25mm and <=3.5mm in lumen diameter and <=30mm in length by visual estimate and within a region up to 5mm to the proximal/distal stent edge;
- •Study target lesion must have undergone coronary interventional treatment >= 4 weeks previously. Patients with one ore more prior PTCA procedures at the target lesion are acceptable candidates.
- •Study target lesion can not be located in a vessel containing another lesion requiring treatment. Lesions located in other vessels may be treated with percutaneous revascularization at the time of the procedure, BUT they must be successfully treated prior to the treatment of the study target lesion;
- •Patient is candidate for a current percutaneous revascularisation technique;
- •Patient is willing to comply with the specified follow-up evaluations (including angiographic follow-up);
- •Patient must provide written informed consent prior to the procedure using a form that is approved by the local Ethics Committee;
排除标准
- •Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK >2 times normal within the preceding 72 hours and the CK enzymes remain above normal at the time of treatment;
- •Has unstable angina classified as Braunwald A I-II-III;
- •Unprotected left main coronary disease with ³50% stenosis;
- •Significant (>50%) stenoses of additional lesions proximal or distal to the target lesion(s) that might require revascularization or impede runoff;
- •Target lesion is in an internal mammary artery, saphenous vein bypass graft or is located in the left main or is ostial;
- •Stent implantation(s) is a non-elective, emergency procedure;
- •Stent at the target restenosed lesion is neither TAXUS™ , CYPHER™ DES nor a BMS;
- •Documented left ventricular ejection fraction <=25%;
- •Totally occluded vessel (TIMI 0 level).
结局指标
主要结局
In stent late loss.
时间窗: between 9 - 12 months
次要结局
- In-stent, in-segment, and in-lesion binary restenosis rate by QCA.(between 9 - 12 months)
- In-lesion late loss as assessed by QCA.(between 9 - 12 months)
- In-stent and in-lesion MLD, and percent diameter stenosis (%DS) as assessed by QCA.(between 9 - 12 months)
- Target lesion revascularization (TLR).(30 days, 6 and 12 months)
- Target vessel revascularization (TVR).(30 days, 6 and 12 months)
- Target vessel failure (TVF) defined as cardiac death, myocardial infarction, or target vessel revascularization.(30 days, 6 and 12 months)
- Composite of Major Adverse Cardiac Events (MACE) defined as cardiac death, myocardial infarction (Q wave and non-Q wave), emergent bypass surgery, or repeat target lesion revascularization.(30 days, 6 months and 12 months)
研究者
研究点 (3)
Loading locations...
相似试验
Unknown
4 期
GISSOC II: Sirolimus Eluting Stent Versus Bare Metal Stent in Chronic Total Coronary OcclusionsCoronary Artery DiseaseNCT00220558Società Italiana di Cardiologia Invasiva150
已完成
4 期
The REALITY Study - Head-to-Head Comparison Between Cypher and TaxusCoronary Artery DiseaseNCT00235092Cordis US Corp.1,335
已完成
4 期
Comparing Angioplasty and DES in the Treatment of Subjects With Ischemic Infrapopliteal Arterial DiseasePeripheral Arterial DiseasesNCT00640770Cordis Corporation200
已完成
3 期
Randomized Clinical Comparison of the Endeavor and the Cypher Coronary Stents in Non-selected Angina Pectoris PatientsIschemic Heart DiseaseNCT00660478Evald Hoej Christiansen2,342
已完成
不适用
The SOURT OUT IV TRIALIschemic Heart DiseaseCoronary AtherosclerosisPercutaneous Coronary InterventionNCT00552877Odense University Hospital2,678